You have read all your free articles, to continue reading subscribe to read the rest of this content.
Mendus has entered into a manufacturing alliance with NorthX Biologics and has announced a directed share issue and a fully secured rights issue of units totaling approximately 317 million SEK in financing. In the alliance with NorthX, Mendus and NorthX will co-establish cell therapy manufacturinAlready a subscriber Login You have…
Swedish biotech company Cantargia recently presented its 2017 Q2 results and it looks like they are ready for their next step, taking them from preclinical to clinical stage. One of the company’s most recent achievements, after the end of Q2, was the patient recruitment to its CANFOUR study. ThAlready a…
Cyxone is revising its previous strategy due to important patent grants and valuable market opportunities. During 2023 a range of new biosimilar disease modifying anti-rheumatic drugs (DMARDs), approved by the US Food and Drug Administration, FDA, have been broadly introduced to the American markAlready a subscriber Login You have read…
Just ten years ago it was hard to predict the progress that has been made within the field of cancer therapy. A cancer vaccine, including a universal cancer vaccine, as the ultimate goal is for many the holy grail, and several Norwegian companies are paving the way. Cancer accounted for…
